The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II study of umbilical cord blood–derived natural killer (CB-NK) cells with elotuzumab, lenalidomide, and high-dose melphalan followed by autologous stem cell transplantation (ASCT) for patients with high-risk multiple myeloma (HRMM).
 
Samer Ali Srour
No Relationships to Disclose
 
Rohtesh S. Mehta
No Relationships to Disclose
 
Nina Shah
Consulting or Advisory Role - Amgen; CareDX; CSL Behring; Genentech/Abbvie; GlaxoSmithKline; Indapta Therapeutics; Karyopharm Therapeutics; Kite, a Gilead company; Oncopeptides; Sanofi
Research Funding - Bluebird Bio; Celgene; Cellectis; Janssen; Nektar; poseida therapeutics; Precision Biosciences; Sutro biopharma; Teneobio
 
Muzaffar H. Qazilbash
No Relationships to Disclose
 
Jin Im
No Relationships to Disclose
 
Qaiser Bashir
No Relationships to Disclose
 
Neeraj Saini
No Relationships to Disclose
 
Yago Nieto
Honoraria - Affimed Therapeutics
Research Funding - Affimed Therapeutics (Inst); AstraZeneca (Inst); Secura Bio (Inst)
 
Issa F. Khouri
No Relationships to Disclose
 
May Daher
No Relationships to Disclose
 
Partow Kebriaei
Honoraria - Kite, a Gilead company; Novartis; Pfizer
Consulting or Advisory Role - Jazz Pharmaceuticals
Research Funding - Amgen; ZIOPHARM Oncology
Travel, Accommodations, Expenses - Kite, a Gilead company; Novartis; Pfizer
 
Uday R. Popat
Research Funding - Abbvie; Bayer; Incyte
 
Elisabet Esteve Manasanch
No Relationships to Disclose
 
Hans C. Lee
Consulting or Advisory Role - Bristol Myers Squibb; Celgene; Genentech; GlaxoSmithKline; Immunitas; Karyopharm Therapeutics; Legend Biotech; Monte Rosa Therapeutics; Oncopeptides; Pfizer; Sanofi; Takeda
Research Funding - Amgen; Celgene; GlaxoSmithKline; Janssen; Regeneron; Takeda
 
Sheeba K. Thomas
Consulting or Advisory Role - BeiGene; Janssen
Research Funding - Ascentage Pharma (Inst); Bristol-Myers Squibb (Inst); Cellectar (Inst); Genentech (Inst); X4 Pharma (Inst)
 
Robert Z. Orlowski
Stock and Other Ownership Interests - Asymmetric Therapeutics
Honoraria - Abbvie; BioTheryX; Bristol-Myers Squibb; GlaxoSmithKline; Karyopharm Therapeutics; Meridian Therapeutics; Monte Rosa Therapeutics; Neoleukin Therapeutics; Oncopeptides; Regeneron; Sanofi/Aventis; Takeda
Consulting or Advisory Role - Abbvie; BioTheryX; Bristol-Myers Squibb; GlaxoSmithKline; Karyopharm Therapeutics; Meridian Therapeutics; Monte Rosa Therapeutics; Neoleukin Therapeutics; Oncopeptides; Regeneron; Sanofi/Aventis
Research Funding - Asymmetric Therapeutics (Inst); BioTheryX (Inst); Heidelberg Pharma (Inst)
Patents, Royalties, Other Intellectual Property - Asymmetric Therapeutics
 
Richard E. Champlin
Consulting or Advisory Role - Actinium Pharmaceuticals; Arog; Johnson & Johnson/Janssen; Kadmon; Omeros
Patents, Royalties, Other Intellectual Property - Royalty from Takeda Corporation
 
Elizabeth J. Shpall
Honoraria - Bayer
Consulting or Advisory Role - • Bayer HealthCare Pharmaceuticals; Adaptimmune; AXIO Research; Fibrobiologics; Navan
Patents, Royalties, Other Intellectual Property - Affimed Therapeutics; Takeda
Travel, Accommodations, Expenses - Magenta Therapeutics; Novartis
 
Katy Rezvani
Consulting or Advisory Role - Adicet Bio; Avenge Bio; Caribou Biosciences; GEMoaB; GlaxoSmithKline; Takeda; Virogen
Research Funding - Affimed Therapeutics; Pharmacyclics; Takeda; Takeda
Patents, Royalties, Other Intellectual Property - License agreement and research agreement with Affimed which creates an institutional conflict of interest under MD Anderson policy.; License agreement and research agreement with Affimed which creates an institutional conflict of interest under MD Anderson policy. (Inst); License agreement and research agreement with Takeda to develop CB-CAR NK cells for the treatment of B-cell malignancies and other cancers, which creates an institutional conflict of interest under MD Anderson policy; License agreement and research agreement with Takeda to develop CB-CAR NK cells for the treatment of B-cell malignancies and other cancers, which creates an institutional conflict of interest under MD Anderson policy (Inst); Patent on generation of BKV CTLs for the treatment of HC or PML; Patent on generation of CAR NK cells